Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly
SNTS [NASD]
Santarus, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E43.18 EPS (ttm)0.50 Insider Own1.10% Shs Outstand63.96M Perf Week-0.55%
Market Cap1.38B Forward P/E16.70 EPS next Y1.29 Insider Trans-87.41% Shs Float61.10M Perf Month-2.31%
Income36.60M PEG2.11 EPS next Q0.17 Inst Own62.00% Short Float4.13% Perf Quarter25.82%
Sales251.50M P/S5.49 EPS this Y285.70% Inst Trans-2.56% Short Ratio1.95 Perf Half Y96.45%
Book/sh1.67 P/B12.93 EPS next Y47.27% ROA23.50% Target Price22.70 Perf Year211.10%
Cash/sh1.53 P/C14.15 EPS next 5Y20.50% ROE44.70% 52W Range4.82 - 24.00 Perf YTD96.63%
Dividend- P/FCF50.40 EPS past 5Y18.20% ROI20.30% 52W High-10.04% Beta1.27
Dividend %- Quick Ratio2.20 Sales past 5Y18.20% Gross Margin65.00% 52W Low347.93% ATR1.00
Employees290 Current Ratio2.40 Sales Q/Q73.00% Oper. Margin15.60% RSI (14)51.82 Volatility3.81% 5.26%
OptionableYes Debt/Eq0.09 EPS Q/Q2884.80% Profit Margin14.60% Rel Volume0.85 Prev Close22.28
ShortableYes LT Debt/Eq0.09 EarningsMay 06 AMC Payout0.00% Avg Volume1.29M Price21.59
Recom1.60 SMA20-1.47% SMA506.40% SMA20058.51% Volume1,094,733 Change-3.10%
07-May-13Reiterated Stifel Buy $20 → $22
05-Mar-13Reiterated Stifel Buy $13 → $15
12-Sep-12Reiterated Stifel Nicolaus Buy $8 → $11
02-Dec-09Reiterated Roth Capital Buy $6 → $7
25-Jun-09Initiated Roth Capital Buy $6
16-Dec-08Initiated Piper Jaffray Neutral
05-Aug-08Reiterated UBS Buy $3.70 → $4
10-Mar-08Upgrade UBS Neutral → Buy
02-Nov-07Reiterated RBC Capital Mkts Outperform $5 → $4
02-Nov-07Reiterated Friedman Billings Outperform $6 → $4
10-Aug-07Downgrade UBS Buy → Neutral $7 → $3
07-Aug-07Reiterated RBC Capital Mkts Outperform $9 → $6
06-Aug-07Reiterated Friedman Billings Outperform $7 → $6
02-Jul-07Upgrade Susquehanna Financial Negative → Neutral
29-Jun-07Upgrade Friedman Billings Mkt Perform → Outperform $7
29-Jun-07Initiated Rodman & Renshaw Mkt Outperform $8
24-May-07Upgrade Merriman Curhan Ford Neutral → Buy
06-Mar-07Reiterated RBC Capital Mkts Outperform $10 → $9
14-Feb-07Initiated Friedman Billings Mkt Perform $7
19-Jun-13 05:40PM  Novo Nordisk Patent Found Invalid Zacks
05:15PM  MediciNova Presents MN-166 Data Zacks
04:55PM  Valeant Raising Funds Zacks
04:35PM  Glaxo Gets Offer for Thrombosis Drugs Zacks
03:40PM  MEIP Starts Phase II Study on Pracinostat Zacks
18-Jun-13 04:35PM  ViroPharma Up on Takeover Rumors Zacks
04:20PM  AstraZeneca and NGM Collaborate Zacks
04:00PM  Positive Data on Incyte's Jakafi Zacks
03:40PM  Data on Astex Candidate Zacks
02:30PM  MannKind Completes Afrezza Studies Zacks
12:15PM  Santarus says FDA accepts Ruconest application AP
11:10AM  Perrigo in Expansion Mode Zacks
10:30AM  Good News for Celgene's Pipeline Zacks
09:07AM  SANTARUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
01:02AM  Santarus and Pharming announce FDA acceptance for review of RUCONEST (recombinant human C1 esterase inhibitor) Biologics License Application Thomson Reuters ONE
01:00AM  Santarus and Pharming Announce FDA Acceptance for Review of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application Business Wire
17-Jun-13 05:00PM  US Launch of Forest's Namenda XR Zacks
02:20PM  XOMA Commences Gevokizumab Study Zacks
10:50AM  Data on BMY/ AbbVie's elotuzumab Zacks
07:30AM  Santarus President & CEO Gerald Proehl Honored as San Diego Ernst & Young Entrepreneur of the Year 2013 in Life Sciences Business Wire
14-Jun-13 04:35PM  New Data on UCB's Cimzia Zacks
13-Jun-13 04:25PM  FDA Panel Meeting for Salix Drug Zacks
02:10PM  Incyte's Jakafi Label Updated Zacks
08:24AM  Santarus price increases positive, says Roth Capital at theflyonthewall.com
12-Jun-13 11:08PM  SANTARUS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Securi EDGAR Online
06:30PM  CRL for AVEO/ALPMY's Tivozanib Zacks
05:10PM  Label Expansion for Roche's RoActemra Zacks
09:40AM  Questcor Surges on Drug Acquisition Zacks
11-Jun-13 05:55PM  AstraZeneca to Buy Pearl Therapeutics Zacks
04:05PM  Tentative Approval for SUPN Candidate Zacks
02:18PM  Commit To Buy Santarus At $17.50, Earn 17.8% Annualized at Forbes
10-Jun-13 05:35PM  Royalty Offer Remains Unattractive to Elan Zacks
05:30PM  Glaxo Reports Disappointing Tykerb Data Zacks
04:35PM  Hyperion Acquires Buphenyl Rights Zacks
04:25PM  Update on Gentium's Defibrotide Zacks
04:10PM  AstraZeneca Resolves Nexium Issue Zacks
03:45PM  Label Expansion Sought for AMAG/TKPYY's Rienso Zacks
09-Jun-13 02:49PM  The Long Case For Santarus at Seeking Alpha
07-Jun-13 04:50PM  BioLineRx Enrolls First Patient in Study Zacks
04:20PM  FDA Panel Positive on GSK's Avandia Zacks
03:45PM  Positive Data on Bayer/REGN's Eye Drug Zacks
12:06PM  Stocks Lean Higher Near Midday; Thor, Hertz Gain In Fast Trade at Investor's Business Daily
10:40AM  Pfizer in $635 Million Deal Zacks
06-Jun-13 06:30PM  Impax Reduces Workforce Zacks
06:10PM  Avanir to Expedite AVP-786 Development Zacks
03:00PM  Endo to Trim Workforce Zacks
11:40AM  Priority Review for AZN/BMY Drug Zacks
05-Jun-13 05:15PM  FDA Issues Warning Letter to Novartis Zacks
04:45PM  AstraZeneca to Return Fostamatinib Rights Zacks
04:35PM  Incyte Presents Positive Jakafi Data Zacks
04:00PM  Astellas' Launch Plans for Acofide Zacks
01:30PM  Stocks Hit New Lows In Afternoon; Hertz Falls 5% at Investor's Business Daily
09:13AM  The Zacks Analyst Blog Highlights: Eli Lilly, Teva, Salix Pharmaceuticals, Santarus and Turkcell Iletisim Hizmetleri Zacks
07:57AM  Monday's Top Biotech Losers Infinity And Synta And Other Top Sells By Fund Managers at Seeking Alpha
04-Jun-13 06:00PM  CHMP Positive on Novartis' Lucentis Zacks
04:40PM  Dr. Reddy's and Fujifilm End JV Zacks
04:20PM  Pipeline Setbacks at Sanofi Zacks
04:15PM  Glaxo/Renaissance Ink Deal Zacks
03:30PM  Incyte Reveals Data on Oncology Candidate Zacks
02:33PM  Eli Lilly's Alimta Disappoints Zacks
03-Jun-13 06:30PM  Positive Data on Bayer/Onyx's Nexavar Zacks
06:15PM  CHMP Backs Celgene's Pomalyst Zacks
06:05PM  AstraZeneca Presents Olaparib Data Zacks
05:55PM  CRL for Endo Health's Aveed Zacks
05:40PM  MannKind Progresses on Afrezza Zacks
05:40PM  Novo Nordisk Seeks IDegLira Approval Zacks
04:10PM  Glaxo Reports Votrient Data Zacks
03:05PM  Roche Presents Data on Avastin Zacks
08:30AM  Data on Merck Candidate at ASCO Zacks
31-May-13 06:12PM  GSK/Genmab Report Positive Arzerra Data Zacks
04:07PM  After Layoffs, Santarus Thrives Due To Its Culture at Investor's Business Daily
03:45PM  Postive Interim Data on Pacira's Exparel Zacks
10:52AM  Jim Cramer: Buy Starbucks, Whole Foods, Saks, and This Solid Stock at Wall St. Cheat Sheet
06:09AM  Cramer's Lightning Round - I Should Have Gone Back To Dover (5/30/13) at Seeking Alpha
30-May-13 06:42PM  Lightning Round: McDonald's, Dover & More at CNBC
06:40PM  [video] Lightning Round at CNBC
06:20PM  NICE News for BMY/AstraZeneca Zacks
06:10PM  Glaxo's Oncology Portfolio Gets a Boost Zacks
05:30PM  Cash and Tysabri Update From Elan Zacks
05:04PM  ANAC's Discussion with FDA for Tavaborole Zacks
04:30PM  Good News for Roche Zacks
04:00PM  Orphan Drug Status for Astellas' Candidate Zacks
03:11PM  Santarus' CEO Presents at the Deutsche Bank 38th Annual Healthcare Conference (Transcript) at Seeking Alpha
29-May-13 06:30PM  Omeros Files CTA for aHUS Candidate Zacks
05:35PM  Dutch Approval for Astellas' Vesomni Zacks
05:10PM  Setback for Valeant Pharma Zacks
03:51PM  Positive Data on Salix's Budesonide Foam Zacks
03:15PM  Encouraging Data from Novartis Zacks
12:00PM  Encouraging Data from Novartis Zacks
28-May-13 07:18PM  Valeant Pharma to Buy Bausch+Lomb Zacks
06:59PM  FDA Accepts Omeros' IND for OMS824 Zacks
05:05PM  Mixed News on Merck's Pipeline Zacks
04:15PM  J&J's Promising Pharma Pipeline Zacks
03:35PM  Obesity Data on Novo Nordisk's Victoza Zacks
11:00AM  AZN Updates on Pulmicort Respules Zacks
24-May-13 03:40PM  Oncogenex to Advance OGX-427 Development Zacks
11:00AM  New Diagnostic Solution from Roche Zacks
09:17AM  Strong Drug Performance Boosts Santarus Higher at Forbes
23-May-13 06:20PM  Pfizer Halts Inotuzumab Study Zacks
05:40PM  Impax Launches Generic Zomig Zacks
Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company offers Uceris extended release tablets for the induction of remission in active, mild to moderate ulcerative colitis; Zegerid to treat certain upper gastrointestinal conditions; and Fenoglide fenofibrate tablets marketed as an adjunct to diet to treat high cholesterol It also provides Glumetza metformin hydrochloride extended release tablets and Cycloset bromocriptine mesylate tablets marketed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In addition, the company focuses on advancing investigational drugs to commercialization, including Ruconest, a recombinant human C1 esterase inhibitor that has completed Phase III clinical study for treatment of acute attacks of angioedema in patients with hereditary angioedema; Rifamycin SV MMX, which has completed Phase III clinical study for treatment of travelers' diarrhea; and SAN-300, an anti-VLA-1 antibody that has completed a Phase I dose-escalation clinical study for the treatment of rheumatoid arthritis. Santarus, Inc. has strategic alliance agreements with MSD Consumer Products, Inc. and Glaxo Group Limited. The company was founded in 1996 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAJun 10Option Exercise2.3610,00023,60058,695Jun 11 06:23 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasJun 10Option Exercise1.1819,00022,420185,326Jun 11 06:49 PM
DE MEULES JULIE ASr. VP, Human ResourcesJun 10Option Exercise1.1813,97416,48915,545Jun 11 06:57 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasJun 10Sale21.4519,000407,504166,326Jun 11 06:49 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAJun 10Sale21.5710,000215,70748,695Jun 11 06:23 PM
DE MEULES JULIE ASr. VP, Human ResourcesJun 10Sale21.6715,165328,654380Jun 11 06:57 PM
Fox Carey JSr VP, General CounselJun 07Option Exercise1.1817,10020,17841,667Jun 10 04:09 PM
Fox Carey JSr VP, General CounselJun 07Sale20.5417,100351,23124,567Jun 10 04:09 PM
Ballard E David IISVP, Med Affairs & Pharm'vigJun 03Option Exercise1.189,00010,6209,000Jun 04 07:07 PM
BURGESS DANIEL DDirectorJun 03Option Exercise3.008,00024,0008,000Jun 04 06:22 PM
DENBY WILLIAM CSr. VP, Commercial OperationsJun 03Option Exercise3.5024,45085,57524,450Jun 04 06:30 PM
BURGESS DANIEL DDirectorJun 03Sale21.348,000170,7260Jun 04 06:22 PM
Ballard E David IISVP, Med Affairs & Pharm'vigJun 03Sale21.349,000192,0950Jun 04 07:07 PM
DENBY WILLIAM CSr. VP, Commercial OperationsJun 03Sale21.4624,450524,6310Jun 04 06:30 PM
Cosmo Technologies Ltd10% OwnerMay 15Sale17.684,887,50086,387,0512,991,044May 15 04:14 PM
Della Cha AlessandroDirectorMay 15Sale21.3316,500351,95049,715May 17 05:07 PM
HERMAN MICHAEL EDirectorMay 14Sale20.7725,000519,33350,000May 15 06:38 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasMay 10Option Exercise3.5018,64365,251184,607May 13 04:39 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasMay 10Sale19.2718,643359,182165,964May 13 04:39 PM
DE MEULES JULIE ASr. VP, Human ResourcesMay 09Option Exercise5.2511,64761,14716,595May 10 04:34 PM
DE MEULES JULIE ASr. VP, Human ResourcesMay 09Sale20.1015,165304,7571,430May 10 04:34 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAMay 08Option Exercise1.8510,00018,48858,593May 09 05:46 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAMay 08Sale20.5310,000205,34448,593May 09 05:46 PM
Fox Carey JSr VP, General CounselMay 07Option Exercise1.1817,10020,17841,234May 08 07:11 PM
Fox Carey JSr VP, General CounselMay 07Sale20.8617,100356,78124,134May 08 07:11 PM
PROEHL GERALD TPresident & CEOMay 06Option Exercise0.8886,60375,778160,740May 07 09:09 PM
Step Michael DSVP, Corporate DevelopmentMay 06Option Exercise1.1830,30135,75531,798May 07 09:12 PM
PROEHL GERALD TPresident & CEOMay 06Sale18.7386,6031,622,46474,137May 07 09:09 PM
Step Michael DSVP, Corporate DevelopmentMay 06Sale18.7430,301567,7011,497May 07 09:12 PM
HALL WARREN ESr. VP, Mfg. & Prod. Dev.May 03Option Exercise3.5027,89497,62938,440May 06 09:35 PM
HALL WARREN ESr. VP, Mfg. & Prod. Dev.May 03Sale18.8928,749543,0749,691May 06 09:35 PM
Ballard E David IISVP, Med Affairs & Pharm'vigMay 02Option Exercise1.189,00010,6209,000May 03 04:56 PM
Ballard E David IISVP, Med Affairs & Pharm'vigMay 02Sale18.459,000166,0270May 03 04:56 PM
DENBY WILLIAM CSr. VP, Commercial OperationsMay 01Option Exercise3.5019,59868,59324,450May 02 04:28 PM
BURGESS DANIEL DDirectorMay 01Option Exercise3.008,00024,0008,000May 02 04:24 PM
DENBY WILLIAM CSr. VP, Commercial OperationsMay 01Sale17.9024,450437,6230May 02 04:28 PM
BURGESS DANIEL DDirectorMay 01Sale17.888,000143,0470May 02 04:24 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasApr 10Option Exercise3.5019,00066,500184,964Apr 11 05:15 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasApr 10Sale16.8219,000319,563165,964Apr 11 05:15 PM
DE MEULES JULIE ASr. VP, Human ResourcesApr 09Option Exercise5.2515,16579,61620,113Apr 10 04:20 PM
DE MEULES JULIE ASr. VP, Human ResourcesApr 09Sale17.0615,165258,7574,948Apr 10 04:20 PM
Fox Carey JSr VP, General CounselApr 08Option Exercise1.1817,10020,17841,234Apr 09 06:45 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAApr 08Option Exercise1.1810,00011,80058,593Apr 09 06:47 PM
Fox Carey JSr VP, General CounselApr 08Sale16.6917,100285,38024,134Apr 09 06:45 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAApr 08Sale16.7010,000167,03048,593Apr 09 06:47 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAApr 05Option Exercise3.0442,744129,94848,593Apr 09 06:47 PM
PROEHL GERALD TPresident & CEOApr 04Option Exercise0.8886,60175,776544,308Apr 05 04:25 PM
PROEHL GERALD TPresident & CEOApr 04Sale16.7586,6011,450,151457,707Apr 05 04:25 PM
Ballard E David IISVP, Med Affairs & Pharm'vigApr 02Option Exercise1.1818,00021,24018,000Apr 03 05:03 PM
Ballard E David IISVP, Med Affairs & Pharm'vigApr 02Sale17.8918,000322,0920Apr 03 05:03 PM
BURGESS DANIEL DDirectorApr 01Option Exercise2.098,00016,7208,000Apr 02 05:26 PM
DENBY WILLIAM CSr. VP, Commercial OperationsApr 01Option Exercise0.883,0462,66529,302Apr 02 05:29 PM
DENBY WILLIAM CSr. VP, Commercial OperationsApr 01Sale17.7524,450433,9954,852Apr 02 05:29 PM
BURGESS DANIEL DDirectorApr 01Sale17.478,000139,7740Apr 02 05:26 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasMar 11Option Exercise3.5019,00066,500184,964Mar 12 04:57 PM
DE MEULES JULIE ASr. VP, Human ResourcesMar 11Option Exercise5.2515,16579,61620,113Mar 12 04:59 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasMar 11Sale15.4419,000293,373165,964Mar 12 04:57 PM
DE MEULES JULIE ASr. VP, Human ResourcesMar 11Sale15.3815,165233,1694,948Mar 12 04:59 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAMar 08Option Exercise1.1810,00011,80015,849Mar 11 04:39 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAMar 08Sale15.4710,000154,6995,849Mar 11 04:39 PM
Fox Carey JSr VP, General CounselMar 07Option Exercise1.4217,10024,35441,234Mar 07 04:49 PM
HERMAN MICHAEL EDirectorMar 07Option Exercise3.2140,000128,250115,000Mar 07 04:53 PM
HERMAN MICHAEL EDirectorMar 07Sale15.2745,000687,04216,000Mar 07 04:53 PM
Fox Carey JSr VP, General CounselMar 07Sale15.2517,100260,73924,134Mar 07 04:49 PM
CARTER MICHAEL GDirectorMar 07Sale15.2232,000487,0400Mar 08 04:11 PM
Step Michael DSVP, Corporate DevelopmentMar 05Option Exercise1.188,94910,56031,798Mar 06 06:03 PM
Step Michael DSVP, Corporate DevelopmentMar 05Sale15.4530,301468,0991,497Mar 06 06:03 PM
Ballard E David IISVP, Med Affairs & Pharm'vigMar 04Option Exercise1.1818,00021,24018,000Mar 05 06:40 PM
HALL WARREN ESr. VP, Mfg. & Prod. Dev.Mar 04Option Exercise3.5028,749100,62239,295Mar 05 06:43 PM
PROEHL GERALD TPresident & CEOMar 04Option Exercise0.8886,60175,776544,308Mar 05 06:46 PM
PROEHL GERALD TPresident & CEOMar 04Sale13.5786,6011,174,803457,707Mar 05 06:46 PM
HALL WARREN ESr. VP, Mfg. & Prod. Dev.Mar 04Sale13.5728,749390,06910,546Mar 05 06:43 PM
Ballard E David IISVP, Med Affairs & Pharm'vigMar 04Sale13.5818,000244,4810Mar 05 06:40 PM
BURGESS DANIEL DDirectorMar 01Option Exercise1.188,0009,4408,000Mar 04 08:07 PM
DENBY WILLIAM CSr. VP, Commercial OperationsMar 01Option Exercise0.8824,45021,39450,706Mar 04 08:13 PM
DENBY WILLIAM CSr. VP, Commercial OperationsMar 01Sale13.3824,450327,16526,256Mar 04 08:13 PM
BURGESS DANIEL DDirectorMar 01Sale13.378,000106,9540Mar 04 08:07 PM
DE MEULES JULIE ASr. VP, Human ResourcesFeb 11Option Exercise5.2515,16579,61620,113Feb 12 04:19 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasFeb 11Option Exercise0.8817,85315,621183,817Feb 12 04:14 PM
DE MEULES JULIE ASr. VP, Human ResourcesFeb 11Sale13.0515,165197,8594,948Feb 12 04:19 PM
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, TreasFeb 11Sale12.9917,853231,941165,964Feb 12 04:14 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAFeb 08Option Exercise1.1810,00011,80015,849Feb 11 04:36 PM
Bedoya-Toro Maria ESVP, Regulatory Affairs & QAFeb 08Sale12.9910,000129,9075,849Feb 11 04:36 PM
Fox Carey JSr VP, General CounselFeb 07Option Exercise2.4817,30042,85241,434Feb 08 05:02 PM
Fox Carey JSr VP, General CounselFeb 07Sale12.7917,300221,24524,134Feb 08 05:02 PM
HERMAN MICHAEL EDirectorFeb 07Sale12.7522,260283,91775,000Feb 08 04:59 PM
HERMAN MICHAEL EDirectorFeb 06Sale12.9767,740878,89397,260Feb 08 04:59 PM
Ballard E David IISVP, Med Affairs & Pharm'vigFeb 04Option Exercise1.1818,00021,24018,000Feb 05 04:17 PM
PROEHL GERALD TPresident & CEOFeb 04Option Exercise0.8886,60175,776544,308Feb 05 04:23 PM
PROEHL GERALD TPresident & CEOFeb 04Sale12.9886,6011,123,787457,707Feb 05 04:23 PM
Ballard E David IISVP, Med Affairs & Pharm'vigFeb 04Sale12.9818,000233,6170Feb 05 04:17 PM
BURGESS DANIEL DDirectorFeb 01Option Exercise1.188,0009,4408,000Feb 04 04:41 PM
DENBY WILLIAM CSr. VP, Commercial OperationsFeb 01Option Exercise0.8824,45021,39450,706Feb 04 04:44 PM
DENBY WILLIAM CSr. VP, Commercial OperationsFeb 01Sale13.3424,450326,18726,256Feb 04 04:44 PM
BURGESS DANIEL DDirectorFeb 01Sale13.288,000106,2450Feb 04 04:41 PM
LOVE TED WDirectorDec 18Buy10.88185,0002,012,800335,500Dec 19 04:09 PM
HALE DAVID FDirectorDec 12Option Exercise2.2584,000188,580304,452Dec 13 04:35 PM
CARTER MICHAEL GDirectorOct 25Option Exercise1.1832,00037,76032,000Oct 26 05:23 PM
HERMAN MICHAEL EDirectorSep 13Option Exercise3.002,0006,000165,000Sep 13 07:48 PM
HERMAN MICHAEL EDirectorSep 12Option Exercise2.4642,000103,290163,000Sep 13 07:48 PM
open in yahoo | open in reuters | open in google